IL-22 CRISPR/Cas9 KO Plasmid (h): sc-403228
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-22 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IL-22 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-22 CRISPR/Cas9 KO Plasmid (h) | sc-403228 | 20 µg | $397.00 |
Overview
Human IL22 encodes interleukin-22 (IL-22), a cytokine predominantly produced by Th17/Th22 cells and innate lymphoid cells that signals through the IL-22R1/IL-10R2 receptor complex on epithelial and stromal compartments. IL-22 activates JAK1/TYK2-dependent STAT3 signaling and intersects with MAPK and PI3K pathways to regulate barrier integrity, antimicrobial peptide expression, mucus production, and tissue repair programs at mucosal surfaces. Dysregulated IL-22 activity has been implicated in inflammatory circuits linking immune cells to epithelia in conditions affecting skin, lung, and gastrointestinal tissues, and it can modulate tumor-associated inflammation and epithelial proliferation depending on context. These properties make IL22 a useful target for dissecting immune–epithelial crosstalk, barrier biology, and cytokine-driven transcriptional responses.
IL-22 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IL22 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IL22 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IL22 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IL-22 protein expression.
This CRISPR knockout system enables efficient generation of IL22-deficient cell models for investigation of IL-22 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IL22 exon(s) critical for IL-22 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IL22 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IL-22 CRISPR/Cas9 KO Plasmid (h) and IL-22 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IL22 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IL-22 HDR Plasmid (h) and IL-22 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IL22 homology arms to support homology-directed repair at defined IL22 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.